Beta Finch - Cigna - CI - EN

More earnings analysis: https://betafinch.com
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown, where we turn dense earnings calls into conversations you'd actually want to listen to. I'm Alex...

**JORDAN:** ...and I'm Jordan. Today we're digging into Cigna's third quarter 2026 results, and Alex, this is a company that's raising guidance while also telling investors "hey, 2027 is going to be a little weird."

**ALEX:** Exactly, lots to unpack. But first, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Good to have that out of the way. So let's get into the numbers.

**ALEX:** Cigna posted adjusted revenue of $73.8 billion for the quarter, adjusted after-tax earnings of $2.1 billion, and adjusted EPS of $7.98. And here's the headline: they raised full-year 2026 EPS guidance to at least $30.60.

**JORDAN:** That's a nice beat-and-raise story. And it's coming from two engines — Evernorth, their health services and pharmacy arm, and Cigna Healthcare, the traditional insurance side. Evernorth revenue grew 6% to $63.8 billion, with pretax earnings of $1.8 billion. Cigna Healthcare revenue was up 9% to $11.7 billion, pretax earnings of $1.2 billion.

**ALEX:** And within Evernorth, the real star was Specialty and Care Services — that's Accredo, their specialty pharmacy, and CuraScript, their distribution business. Pretax earnings there grew 15% year-over-year to $1.1 billion.

**JORDAN:** That's being driven by biosimilars and specialty generics hitting their stride. Generic Revlimid, a big oncology drug, is now at about 90% penetration. Biosimilar Humira and Stelara are seeing strong adoption too, especially with Cigna offering zero-dollar out-of-pocket options for patients.

**ALEX:** It's a good reminder that the "boring" parts of healthcare — drug substitution, supply chain efficiency — can actually be huge profit drivers.

**JORDAN:** Right, and on the Cigna Healthcare side, their medical care ratio — basically how much premium revenue goes out the door in claims — came in at 85%, right in line with expectations. Medical customers grew 2% year-to-date to 18.5 million, with particularly strong growth in their Select segment, which serves smaller employers.

**ALEX:** Now let's talk strategy, because CEO Brian Evanko spent a lot of time on something called "Lead to 1." It's their big vision going forward.

**JORDAN:** Lead to 1 is essentially about personalization at scale using data and AI. The stat that jumped out at me: 8% of patients account for 55% of total healthcare spending. So the whole strategy is built around identifying those complex, high-cost patients earlier and intervening before costs spiral.

**ALEX:** They launched something called HealthSense in September — a tool that connects a patient's health needs, benefits, pharmacy coverage, and claims history so clinical teams get the full picture. It's starting with oncology.

**JORDAN:** And they gave some compelling numbers around this — an integrated cancer patient journey can save $28,000 per person per year. That's not a typo, that's the scale of savings they're talking about for complex care coordination.

**ALEX:** The other big strategic story is the "Signature" model — this is Cigna's attempt to reinvent pharmacy benefits. Instead of the traditional rebate-driven system, it's a fee-based, transparent model.

**JORDAN:** Which matters because, let's be honest, PBMs have taken a lot of regulatory and public heat for opacity. Signature is designed to guarantee patients the lowest available out-of-pocket cost on prescriptions — they're calling it "Price Assure," and it's already saving about 30% on high-cost branded drugs for the rou

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and joining me as always is my co-host Jordan. Today we're diving into Cigna Group's Q1 2026 earnings call - and wow, there's a lot to unpack here, including some major leadership changes and strategic pivots.

But before we jump in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Thanks Alex. And speaking of major changes, this earnings call was pretty historic - it was CEO David Cordani's final quarterly call after 17 years leading the company. But the numbers certainly gave him a strong send-off.

ALEX: Absolutely! So let's start with the headline numbers. Cigna reported Q1 revenue of $68.5 billion and adjusted EPS of $7.79. That EPS represents 16% year-over-year growth, which is pretty impressive. And based on this strong performance, they raised their full-year 2026 EPS guidance to at least $30.35.

JORDAN: What's interesting is that both of their main segments - Evernorth and Cigna Healthcare - performed above internal expectations. Evernorth earnings were slightly ahead, while Cigna Healthcare really exceeded expectations with 18% earnings growth year-over-year. The medical care ratio came in at 79.8%, which was better than their guidance of slightly below 81%.

ALEX: Now Jordan, there were some significant strategic announcements that I think investors need to pay attention to. Can you walk us through those?

JORDAN: Sure thing. Cigna made two big portfolio moves. First, they're planning to exit the individual exchange business at the end of 2026. This isn't a huge surprise - it's been a small and shrinking business for them. CEO-elect Brian Evanko said they couldn't see a clear path to scale it meaningfully within Cigna's overall size.

The second move is potentially bigger - they announced a strategic review for eviCore, which handles prior authorization services for multiple health plans. This seems to be driven by the industry's progress on standardizing and automating prior authorization processes.

ALEX: And these moves really fit into their broader strategy of portfolio shaping, right? They're focusing resources on their three core growth platforms.

JORDAN: Exactly. Evanko outlined those three platforms clearly: Specialty and Care Services, which represents about 35% of company income and is growing 8-12% annually; Pharmacy Benefit Services at about 25% of income; and Cigna Healthcare at 40% of income. They're essentially doubling down on what's working and shedding what isn't.

ALEX: Let's talk about that specialty business because it really shone this quarter. Specialty and Care Services earnings grew 20% to $1.1 billion. What's driving that?

JORDAN: Three main factors. First, solid specialty volume growth across the board. Second - and this is interesting - continued adoption of biosimilars and specialty generics. These deliver savings to patients while actually improving margins for Cigna. Third, they're getting contributions from their investment in Shields Health Solutions, which they made late last year.

David Cordani specifically highlighted how they're using AI to improve biosimilar conversions. For drugs like Humira and Stelara, they're offering $0 out-of-pocket costs to patients while using AI to identify personalized conversion strategies. It's a win-win - lower costs, higher patient satisfaction, and better margins.

ALEX: That ties into something Brian Evanko emphasized about the future - this focus on AI and data analytics. He's clearly putting his stamp on the company's direction.

JORDAN: Right. When he takes over as CEO in July, Evanko outlined three areas of intensification: better use of data and AI for personalized care, drivin

This episode includes AI-generated content.

**Beta Finch Podcast Script**

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the latest corporate results to help you understand what's moving the markets. I'm Alex, and I'm joined by my co-host Jordan. Today we're breaking down Cigna Group's fourth quarter 2025 earnings call - and folks, there's a lot to unpack here.

Before we dive in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely, Alex. And wow, what a call this was! Cigna just delivered some impressive numbers while simultaneously announcing a massive $7 billion settlement with the FTC. It's like they cleared two major hurdles in one earnings cycle.

**ALEX:** Right? So let's start with the headline numbers. Cigna reported full-year adjusted revenue of $275 billion - that's 11% growth year-over-year. Adjusted earnings per share came in at $29.84, up 9%. For 2026, they're guiding to at least $30.25 per share. Jordan, those are some solid numbers in what CEO David Cordani called a "pivotal year."

**JORDAN:** They really are, Alex. And what caught my attention is how they're managing this transformation while maintaining growth. The company is essentially reinventing their pharmacy benefits model - moving to what they call a "rebate-free" system - while still hitting their financial targets. That takes some serious execution capability.

**ALEX:** Let's talk about that FTC settlement because it's huge. $7 billion in out-of-pocket cost relief over ten years for 100 million customers. Cordani was pretty emphatic that this positions them well for their new pharmacy model they announced back in 2025. It sounds like they saw this regulatory wave coming and built their strategy around it.

**JORDAN:** Exactly. And here's what's fascinating - they're saying this settlement actually aligns perfectly with their new business model. Instead of fighting the regulatory tide, they're riding it. The new model eliminates rebates, increases transparency, and supposedly keeps similar margin profiles. During the Q&A, analyst Lisa Gill pressed them on this, and Cordani was confident that the margin profile will remain similar even with this massive shift.

**ALEX:** That's a bold claim. They're basically saying they can completely transform how they do business while maintaining profitability. The specialty pharmacy business seems to be a big driver here - 14% revenue growth and they mentioned 13% growth in specialty scripts.

**JORDAN:** The specialty business is really their growth engine. It's gone from about 25% of the company three years ago to 35% now. Brian Evanko, the COO, highlighted that this is a $400 billion addressable market growing at high single digits. They're particularly bullish on biosimilars - expecting over $100 billion in savings from biosimilar adoption by 2030.

**ALEX:** Speaking of Evanko, he also mentioned some interesting tech innovations. They're rolling out AI-powered digital tools, including a provider matching tool and real-time cost tracking. Plus they launched something called "Clarity" - a new healthcare offering with transparent pricing that they claim can save clients up to 10% in medical costs.

**JORDAN:** The Clarity product is intriguing because it represents this broader shift toward transparency that seems to be driving everything Cigna is doing right now. No referrals needed, simple co-pay structure, single digital platform. It feels like they're trying to simplify healthcare, which honestly, is desperately needed.

**ALEX:** Now, let's talk about some challenges. The medical care ratio guidance for 2026 is 83.7% to 84.7%, which analyst Kevin Fischbeck questioned. CFO Ann Dennison explained they're being prudent about elevated cost trends, even with repricing

This episode includes AI-generated content.

Stay tuned for AI-powered earnings analysis from Beta Finch.

This episode includes AI-generated content.